The key is its use of molecular testing that looks for a small section of the SARS-CoV-2 virus’ RNA and amplifying that segment until there’s enough to detect. Other testing methods can take hours or days to produce viable results.
Abbott is in the midst of ramping up production and expects to deliver 50,000 of the tests per day in the US as of next week. However, one of its greatest advantages may be its existing footprint. The ID NOW platform already has the “largest” molecular testing presence in the US, and is already “widely available” in doctors’ offices and emergency rooms. If all goes well, the US could both have a more accurate representation of the pandemic’s scope and ensure that the infected get the right care as quickly as possible.